Original Article

Eradication Rate of Helicobacter pylori on the US–Mexico Border Using the Urea Breath Test

Authors: Roy P. Liu, MD, Roberta Romero, DNP, Jerzy Sarosiek, MD, Christopher Dodoo, MS, Alok K. Dwivedi, PhD, Marc J. Zuckerman, MD

Abstract

Objectives: Helicobacter pylori is prevalent worldwide, especially in Latin America. Triple and quadruple antibiotic therapies have been relatively effective; however, resistance has emerged in recent years. The treatment success rate of these regimens on the border of the United States and Mexico is unknown. Our study attempted to determine eradication rates of two major regimens based on urea breath test (UBT) results in patients previously diagnosed as having H. pylori in a single center in El Paso, Texas, a city on the geographic border with Mexico.

Methods: This was a retrospective cohort study of adult patients with H. pylori who underwent UBT after being treated with triple therapy (amoxicillin/clarithromycin/proton pump inhibitor for 14 days), quadruple therapy (tetracycline/metronidazole/bismuth/proton pump inhibitor, usually for 10 days), or both for H. pylori from 2010 to 2015 in a county hospital. Patients were excluded if they did not complete therapy or if their treatment regimen was unknown. The Student t test and the χ2 test were used to analyze the data. The cumulative incidence and 95% confidence interval (CI) for treatment success were estimated.

Results: A total of 104 patients completed the treatment for H. pylori and had UBT. Mean age was 53 years, 76% were women, 85% were Hispanic, and mean body mass index was 30.5 kg/m2. Of the 104 patients diagnosed as having H. pylori, 88 received triple therapy (84.6%) and 16 received quadruple therapy: 12 (11.5%) standard quadruple therapy, 4 (3.9%) triple therapy plus metronidazole. There were no differences between groups regarding age, sex, body mass index, or ethnicity. Overall, 90 (86.5%, 95% CI 78–92) patients had negative UBT after initial treatment. Based on posttreatment UBT, the triple therapy group had a similar eradication rate compared with the quadruple therapy group (78/88, 88.6% vs 12/16, 75.0%, P = 0.22). Of the 14 patients with positive posttreatment UBT, 12 (85.7%) received retreatment (2 were lost to follow-up), 11 (91.7%) received quadruple therapy, and 1 (8.3%) received triple therapy. Eradication was successful in 9 of 12 (75%, 95% CI 43–95) patients at retreatment. As such, of the initial 104 patients, 99/104 (95.2%) achieved H. pylori eradication posttreatment (either initial or retreatment).

Conclusions: In a predominantly Hispanic population on the US–Mexico border, H. pylori eradication rates based on UBT results were relatively high and were similar for triple therapy and quadruple therapy. Quadruple therapy was effective for those who failed the initial H. pylori treatment. This may have implications for cost-effective therapy in our region.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Peleteiro B, Bastos A, Ferro A, et al. Prevalence of Helicobacter pylori infection worldwide: a systemic review of studies with national coverage. Dig Dis Sci 2014;59:1698-1709.
 
2. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012;13:607-615.
 
3. Graham DY. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology 2015;148:719-731.e3.
 
4. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-1153.
 
5. Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011;378:507-514.
 
6. Salazar CO, Cardenas VM, Reddy RK, et al. Greater than 95% success with 14-day bismuth quadruple anti- Helicobacter pylori therapy: a pilot study in US Hispanics. Helicobacter 2012;17:382-390.
 
7. Cardenas VM, Graham DY, El-Zimaity HM, et al. Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border. Aliment Pharmacol Ther 2006;23:295-301.
 
8. Dwivedi AK, Mallawaarachchi I, Lee S, et al. Methods for estimating relative risk in studies of common binary outcomes. J Appl Stat 2013;41:484-500.
 
9. Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374-1384.
 
10. Torres J, Camorlinga-Ponce M, Perez-Perez G, et al. Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J Clin Microbiol 2001;39:2677-2680.
 
11. Alvarez A, Moncayo JI, Santacruz JJ, et al. Antimicrobial susceptibility and mutations involved in clarithromycin resistance in Helicobacter pylori isolates from patients in the western central region of Colombia. Antimicrob Agents Chemother 2009;53:4022-4024.
 
12. Saracino IM, Zullo A, Holton J, et al. High prevalence of primary antibiotic resistance in Helicobacter pylori isolates in Italy. J Gastrointestin Liver Dis 2012;21:363-365.
 
13. Biernat MM, Poniewierka E, Blaszczuk J, et al. Antimicrobial susceptibility of Helicobacter pylori isolates from Lower Silesia, Poland. Arch Med Sci 2014;10:505-509.
 
14. Farina N, Kasamatsu E, Samudio M, et al. Antimicrobial susceptibility of H pylori strains obtained from Paraguayan patients. Rev Med Chil 2007;135:1009-1014.
15. Tanih NF, Ndip RN. Molecular detection of antibiotic resistance in South African isolates of Helicobacter pylori. Gastroenterol Res Pract 2013;2013:259457.
 
16. Xin Y, Manson J, Govan L, et al. Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis. BMC Gastroenterol 2016;16:80.
 
17. Zhang ZF, Zhao G, Liu LN. Effectiveness and safety of proton pump inhibitor and levofloxacin based first-line triple therapy in the eradication of Helicobacter pylori : a meta-analysis. Zhonghua Yi Xue Za Zhi 2008;88:2722-2725.
18. Gou QY, Shi RH, Yu RB. Levofloxacin containing triple therapy vs standard triple therapy for eradication of Helicobacter pylori : a meta-analysis. Shi Jie Hua Ren Xiao Hua Za Zhi 2014;22:5207-5211.
19. Wenzhen Y, Kehu Y, Bin M, et al. Moxifloxacin-based triple therapy versus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection: a meta-analysis of randomized controlled trials. Intern Med 2009;48:2069-2076.
 
20. Ye CL, Liao GP, He S, et al. Levofloxacin and proton pump inhibitor-based triple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Pharmacoepidemiol Drug Saf 2014;23:443-455.
 
21. Peedikayil MC, Alsohaibani FI, Alkhenizan AH. Levofloxacin-based first-line therapy versus standard first-line therapy for Helicobacter pylori eradication: meta-analysis of randomized controlled trials. PLoS One 2014;9:e85620.
 
22. Xiao SP, Gu M, Zhang GX. Is levofloxacin-based triple therapy an alternative for first-line eradication of Helicobacter pylori ? A systematic review and meta-analysis. Scand J Gastroenterol 2014;49:528-538.
 
23. Zhang G, Zou J, Liu F, et al. The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials. Braz J Med Biol Res 2013;46:607-613.
 
24. Nyssen OP, McNicholl AG, Megraud F, et al. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev 2016;6:CD009034.
 
25. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014;12:177-186.e3.
 
26. Larsen AL, Ragnhildstveit E, Moayeri B, et al. Resistance rates of metronidazole and other antibacterials in Helicobacter pylori from previously untreated patients in Norway. APMIS 2013;12:353-358.
 
27. Eisig JN, Silva FM, Barbuti RC, et al. Helicobacter pylori antibiotic resistance in Brazil: clarithromycin is still a good option. Arq Gastroenterol 2011;48:261-264.
 
28. Godoy AP, Ribeiro ML, Benvengo YH, et al. Analysis of antimicrobial susceptibility and virulence factors in Helicobacter pylori clinical isolates. BMC Gastroenterol 2003;3:20.
 
29. Torres-Debat ME, Perez-Perez G, Olivares A, et al. Antimicrobial susceptibility of Helicobacter pylori and mechanisms of clarithromycin resistance in strains isolated from patients in Uruguay. Rev Esp Enferm Dig 2009;101:757-762.
 
30. Shaikh T, Fallone CA. Effectiveness of second through sixth line salvage Helicobacter pylori treatment: bismuth quadruple therapy is almost always a reasonable choice. Can J Gastroenterol Hepatol 2016;2016:7321574.
 
31. Chey WD, Leontiadis GI, Howden CW, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol 2017;112:212-239.